Summary
The AI claims provided are about TYKERB coupon/savings card logistics and eligibility, but the supplied FDA prescribing information excerpts relate to hepatotoxicity and hepatic impairment. None of the coupon program statements are supported or contradicted by the provided label text.
Category Scores
Accurate Statements
Unsupported Statements
"Tykerb coupon" usually means a manufacturer-sponsored or pharmacy savings card that can reduce the out-of-pocket price for people with a prescription for Tykerb (lapatinib).
No coupon/savings card or out-of-pocket pricing information is present in the provided prescribing information excerpts.
The availability and value of Tykerb coupons can change frequently based on the drug’s current pricing, payer rules, and eligibility requirements.
The provided label excerpts do not address coupon availability/value or how it may change.
Tykerb coupons are generally meant to help with the cost the patient pays after insurance rules.
The provided label excerpts do not describe any patient cost assistance program mechanics.
Some savings cards apply only when there is no insurance coverage or only cover specific plan types.
No savings card eligibility/plan-type restrictions are mentioned in the provided label excerpts.
Some savings cards may be restricted for patients on certain government programs.
No government-program restrictions for coupon programs are mentioned in the provided label excerpts.
Coupon programs often include eligibility requirements such as commercial insurance and not government insurance.
No coupon program eligibility criteria are mentioned in the provided label excerpts.
Coupon programs may be not valid with certain coverage or for specific plan types.
No coverage/plan-type validity statements about coupon programs appear in the provided label excerpts.
Coupon programs may limit the maximum monthly discount or the number of fills.
No coupon limits (monthly discount, number of fills) are mentioned in the provided label excerpts.
Coupon programs may require the use of a participating pharmacy or a specific claim process.
No coupon program participation pharmacy or claim process details are mentioned in the provided label excerpts.
If a generic lapatinib option is available in the market, pricing can shift and coupons may be less common or less generous.
The provided label excerpts do not address generic availability, pricing dynamics, or coupon program generosity changes.
Coupon programs tend to change when patent/exclusivity or pricing dynamics change.
The provided label excerpts do not address patent/exclusivity or pricing-driven coupon program changes.
Contradictions
Important Omissions
No FDA label-aligned information is provided regarding TYKERB hepatotoxicity monitoring, dose modification for hepatic impairment, or discontinuation/non-retreatment guidance; instead, the response focuses on coupon program details not covered by the supplied label excerpts.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The evaluated claims are about coupon program logistics and do not describe drug safety or dosing. While unsupported by the provided label excerpts, they are unlikely to directly alter prescribing decisions based on the supplied FDA safety text.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Coupon/savings-card claims are not supported by the provided FDA prescribing information excerpts.
Suggested Improvement
Limit statements to topics actually present in the supplied label (e.g., hepatotoxicity monitoring and discontinuation/non-retreatment for severe hepatotoxicity; dose reduction considerations in severe hepatic impairment) or provide the correct label sections if evaluating coupon-related claims.